• Je něco špatně v tomto záznamu ?

Does Pathological Complete Response after Neoadjuvant Therapy Influence Postoperative Morbidity in Rectal Cancer after Transanal Total Mesorectal Excision

M. Svoboda, V. Procházka, T. Grolich, T. Pavlík, M. Mazalová, Z. Kala

. 2023 ; 54 (2) : 528-535. [pub] 20220507

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23017076

PURPOSE: It is still unclear if pathological complete response (pCR) after neoadjuvant chemoradiotherapy (CRT) in patients treated for rectal cancer causes worse postoperative outcomes, especially after transanal total mesorectal excision (TaTME). Worse postoperative outcomes might be an argument for an organ preserving watch and wait strategy in fragile patients and patients with comorbidities. The aim of this study is to evaluate whether patients treated for rectal cancer who had pCR to neoadjuvant therapy develop worse postoperative outcomes after TaTME than patients without complete response. METHODS: Comparative retrospective analysis (with nearest neighbor matching algorithm) of postoperative outcomes in two groups of patients, with pCR, n = 15 and without pCR (non-pCR), n = 57. All patients were operated on only by one surgical approach, TaTME, for middle and distal rectal tumors. All procedures were performed by one surgical team between 2014 and 2020 at the University Hospital Brno in Czech Republic. RESULTS: Overall morbidity was comparable between the groups (pCR group - 53.8% vs. non-pCR - 38.6%, p = 0.381). Anastomotic leak (AL) was observed in 33.3% of patients with pCR and in 17.5% of patients in the non-pCR group without statistical significance (p = 0.281). CONCLUSION: In conclusion, pathological complete response after neoadjuvant therapy does not appear to affect postoperative morbidity in rectal cancer after TaTME. Therefore, in patients with complete response who are not adherent to W&W surveillance, surgical resection can be perform without increased postoperative complications.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23017076
003      
CZ-PrNML
005      
20231026105423.0
007      
ta
008      
231013s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s12029-022-00826-y $2 doi
035    __
$a (PubMed)35524090
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Svoboda, Martin $u Department of Surgery, Faculty of Medicine, University Hospital Brno Bohunice, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000156073450
245    10
$a Does Pathological Complete Response after Neoadjuvant Therapy Influence Postoperative Morbidity in Rectal Cancer after Transanal Total Mesorectal Excision / $c M. Svoboda, V. Procházka, T. Grolich, T. Pavlík, M. Mazalová, Z. Kala
520    9_
$a PURPOSE: It is still unclear if pathological complete response (pCR) after neoadjuvant chemoradiotherapy (CRT) in patients treated for rectal cancer causes worse postoperative outcomes, especially after transanal total mesorectal excision (TaTME). Worse postoperative outcomes might be an argument for an organ preserving watch and wait strategy in fragile patients and patients with comorbidities. The aim of this study is to evaluate whether patients treated for rectal cancer who had pCR to neoadjuvant therapy develop worse postoperative outcomes after TaTME than patients without complete response. METHODS: Comparative retrospective analysis (with nearest neighbor matching algorithm) of postoperative outcomes in two groups of patients, with pCR, n = 15 and without pCR (non-pCR), n = 57. All patients were operated on only by one surgical approach, TaTME, for middle and distal rectal tumors. All procedures were performed by one surgical team between 2014 and 2020 at the University Hospital Brno in Czech Republic. RESULTS: Overall morbidity was comparable between the groups (pCR group - 53.8% vs. non-pCR - 38.6%, p = 0.381). Anastomotic leak (AL) was observed in 33.3% of patients with pCR and in 17.5% of patients in the non-pCR group without statistical significance (p = 0.281). CONCLUSION: In conclusion, pathological complete response after neoadjuvant therapy does not appear to affect postoperative morbidity in rectal cancer after TaTME. Therefore, in patients with complete response who are not adherent to W&W surveillance, surgical resection can be perform without increased postoperative complications.
650    _2
$a lidé $7 D006801
650    _2
$a rektum $x chirurgie $x patologie $7 D012007
650    _2
$a neoadjuvantní terapie $7 D020360
650    _2
$a retrospektivní studie $7 D012189
650    12
$a nádory rekta $x chirurgie $x patologie $7 D012004
650    _2
$a pooperační komplikace $x epidemiologie $x etiologie $7 D011183
650    _2
$a morbidita $7 D009017
650    12
$a laparoskopie $x metody $7 D010535
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
700    1_
$a Procházka, Vladimír $u Department of Surgery, Faculty of Medicine, University Hospital Brno Bohunice, Masaryk University, Brno, Czech Republic. prochazka.vladimir@fnbrno.cz $1 https://orcid.org/0000000177476072
700    1_
$a Grolich, Tomáš $u Department of Surgery, Faculty of Medicine, University Hospital Brno Bohunice, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000154655879
700    1_
$a Pavlík, Tomáš $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic $1 https://orcid.org/000000017166032X
700    1_
$a Mazalová, Monika $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Kala, Zdeněk $u Department of Surgery, Faculty of Medicine, University Hospital Brno Bohunice, Masaryk University, Brno, Czech Republic $1 https://orcid.org/000000034187388X
773    0_
$w MED00204612 $t Journal of gastrointestinal cancer $x 1941-6636 $g Roč. 54, č. 2 (2023), s. 528-535
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35524090 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231013 $b ABA008
991    __
$a 20231026105418 $b ABA008
999    __
$a ok $b bmc $g 2000549 $s 1203438
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 54 $c 2 $d 528-535 $e 20220507 $i 1941-6636 $m Journal of gastrointestinal cancer $n J Gastrointest Cancer $x MED00204612
LZP    __
$a Pubmed-20231013

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...